Somnomed (SOM.AX)

Executive Summary

Somnomed is the global leader in oral appliance therapy for obstructive sleep apnea (OSA), offering a comfortable and effective alternative to CPAP. Its flagship product, SomnoDent Avant, is a mandibular advancement device (MAD) that holds a strong market position across 28 countries. Despite growing awareness of OSA, CPAP remains the gold standard, limiting Somnomed's penetration. The company is private but listed on the ASX (SOM.AX) with a market cap of ~$125M. Revenue growth has been steady, driven by direct sales and partnerships, but competitive pressure from other MAD manufacturers and CPAP innovations persists. Key challenges include limited reimbursement in some regions and the need for physician education.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for next-generation SomnoDent Avant with enhanced comfort features70% success
• 2027Expansion into China through regulatory approval and distribution partnerships50% success
• Q4 2026Positive 12-month data from head-to-head trial against CPAP demonstrating non-inferiority60% success